• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Audrey Abelleira, PharmD, BCPP

Audrey Abelleira, PharmD, BCPP

Articles

ARTICLES

Clinical Update

Inpatient Use of Benzodiazepines for Patients With Substance Use Disorders

January 31, 2024
Audrey Abelleira, PharmD, BCPP
From The Carlat Hospital Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, VA Connecticut Healthcare System; clinical instructor, Yale School of Medicine, New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

Benzodiazepines are highly beneficial for managing anxiety and agitation in psychiatric inpatient settings, but we must be cautious about prescribing them to patients with substance use disorders (SUDs). Here we review strategies to reduce the risk of benzodiazepine misuse and discuss alternative medication options, including second-generation antipsychotics, antidepressants, gabapentin, and pregabalin.


Read More
Expert Q&A

Deprescribing Benzos: A How-To Guide

October 31, 2023
Audrey Abelleira, PharmD, BCPP
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

QA_Addiction--Prescriptions_Abelleira.jpgAudrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, VA Connecticut Healthcare System; clinical instructor, Yale School of Medicine, New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.


Benzodiazepines are widely prescribed but carry significant risks. The best course of action for many patients is to have their benzodiazepine prescription discontinued, but physiologic dependence can make stopping benzodiazepines a big challenge. Dr. Abeillera teaches us how to identify those who might benefit from a taper and covers all the details on how to do it as safely and effectively as possible. 


Read More
EHSStockphoto_Shutterstock_498009256.jpg
Clinical Update

Benzodiazepines: The Basics and Beyond

October 31, 2023
Audrey Abelleira, PharmD, BCPP
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, VA Connecticut Healthcare System; clinical instructor, Yale School of Medicine, New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

Benzodiazepines vary widely in their pharmacologic properties such as half-life, lipophilicity, and medication interactions. Here, we review the essential pharmacology of the prominent benzodiazepine agents and draw clinical correlates to how these properties translate to patient care.


Read More
CLINICAL UPDATE

Alcohol Use Disorder and Thiamine Supplementation

January 30, 2023
Audrey Abelleira, PharmD, BCPP
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, Pain Management and Opioid Safety Program Coordinator, VA Connecticut Healthcare System. Clinical instructor, Yale School of Medicine. New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

We all learn that patients with alcohol use disorder should receive thiamine supplementation. But why, and how should it be given? We discuss the pathophysiology that underlies thiamine deficiency in alcohol use disorder and why it is so important. We then go over the latest thiamine supplementation guidelines.


Read More
CLINICAL UPDATE

What to Know About Injectable Buprenorphine (Sublocade)

January 30, 2023
Audrey Abelleira, PharmD, BCPP
From The Carlat Addiction Treatment Report
Issue Links: Editorial Information | PDF of Issue

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, Pain Management and Opioid Safety Program Coordinator, VA Connecticut Healthcare System. Clinical instructor, Yale School of Medicine. New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

Various formulations of buprenorphine abound, and a new long-acting injectable form (Sublocade) is one of the latest arrivals. But does it actually work? Here, we review the pharmacology behind it, go over efficacy data, and provide guidance on how to decide when to consider long-acting injectable buprenorphine for your patients.



Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.